Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203100 | 0.90 | CRHR1 (0.40) | TLR7TLR8CRHR1 | |
| SCHEMBL7476643 | 0.88 | CRHR1 (0.44) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL7475052 | 0.88 | TLR7 (0.38) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL6202548 | 0.88 | TLR7 (0.38) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL6203573 | 0.88 | TLR7 (0.41) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL6201715 | 0.86 | CRHR1 (0.39) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL7478618 | 0.86 | CRHR1 (0.42) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL6203930 | 0.86 | TLR7 (0.44) | TLR7TLR8CRHR1POLB | |
| SCHEMBL6201435 | 0.85 | CRHR1 (0.41) | TLR7TLR8CRHR1ALDH1A1POLB | |
| SCHEMBL6204471 | 0.85 | TLR7 (0.42) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |